Full-Time

Etmf Specialist

Confirmed live in the last 24 hours

Relay Therapeutics

Relay Therapeutics

201-500 employees

Biotech company focused on drug discovery

Biotechnology
Healthcare

Mid

Cambridge, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary

You match the following Relay Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 2-5 years industry experience with TMF/eTMF
  • Hands-on experience with TMF QC processes, including both individual document quality checks and TMF completeness reviews
  • Working knowledge of ICH-GCP, FDA, and EMA regulations
  • Working knowledge of the CDISC TMF Reference Model
  • Veeva Vault eTMF experience a plus
  • Excellent organizational skills with the ability to multi-task and prioritize effectively in an extremely fast-paced and dynamic environment
  • Outstanding verbal and written communication skills
  • Strong work ethic, excellent problem-solving ability, and attention to detail and quality are critical to success
Responsibilities
  • Engage in assessing eTMF metrics for completeness, timeliness, and quality
  • Facilitate TMF QC Reviews and ensure issues identified are tracked to resolution
  • Help build and maintain strong partnership with key stakeholders to ensure cross-functional eTMF engagement
  • Engage with CROs/Vendors to ensure responsibilities around eTMF are clearly defined and executed
  • Contribute to eTMF study creation, maintenance, and archival, ensuring all activities are performed in accordance with Relay’s Standard Operating Procedures (SOPs), ICH-GCP Guidelines, EMA, FDA, and other health authority requirements
  • Help identify business needs to assess the current state of eTMF and identify opportunities for process improvement, ensuring industry best practice is implemented
  • Participate in the creation and review of Study-specific eTMF Plans, Study-specific TMF Indexes, and QC approach across all studies
  • Participate in discussions with IT and eTMF system managed services relations and topics
  • May participate in health authority inspections and audits
Desired Qualifications
  • Veeva Vault eTMF experience a plus

Relay Therapeutics focuses on drug discovery by emphasizing the movement of proteins in its research. The company uses its Dynamo™ platform, which integrates experimental and computational methods, to identify and develop new drugs, particularly for complex diseases that are hard to treat with current therapies. This platform enables Relay to target proteins that have previously been difficult to address, expanding treatment options in areas like precision oncology and genetic diseases. Unlike many competitors, Relay's approach is centered on understanding protein dynamics, which allows for more effective drug development. The company's goal is to create impactful medicines for patients, and it is engaged in clinical trials to ensure the safety and effectiveness of its drug candidates.

Company Size

201-500

Company Stage

IPO

Total Funding

$535M

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery complements Relay's computational techniques, enhancing drug development.
  • Quantum computing integration could boost Dynamo's capabilities in drug discovery.
  • Rising personalized medicine trend aligns with Relay's precision medicine focus.

What critics are saying

  • Increased competition from VantAI threatens Relay's market position.
  • Layoffs may impact Relay's operational efficiency and research progress.
  • Reliance on public offerings suggests potential financial instability for Relay.

What makes Relay Therapeutics unique

  • Relay's Dynamo platform targets previously undruggable proteins, expanding treatment possibilities.
  • Focus on protein motion places Relay at the forefront of innovative drug discovery.
  • Relay's precision oncology approach tailors treatments to individual genetic profiles.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, vision

Life, disability, & FSA

401k

Commuter benefits

Parental leave

Home office stipend

Tuition reimbursement

PTO

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

2%
Pattern of USA
Oct 7th, 2024
Job Reductions Update: Kaléo to Cut 58 Positions, Ongoing Layoffs at Stryker

Relay Therapeutics has announced it will be laying off about 10% of its workforce, impacting approximately 30 employees, as confirmed by a spokesperson in a statement to BioSpace.

Relay TX
Sep 18th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock | Relay Therapeutics

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten

GlobeNewswire
Sep 11th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Therapeutics announces pricing of public offering of common stock.

Stock Titan
Sep 11th, 2024
Relay Therapeutics Announces Pricing of Public Offering of Common Stock | RLAY Stock News

Relay Therapeutics announces $200M public offering of 28.5M shares at $7 each. Learn how this biotech firm plans to use the funds and what it means for investors. Closing expected Sept 12.

Tech Times New York
Sep 9th, 2024
Relay Therapeutics Announces Proposed Public Offering of Common Stock

Relay Therapeutics announces proposed public offering of common stock.